Investing in innovators: Learn more about the Cancer Immunotherapy ETF’s components with our exclusive series of CEO interviews below.
Gene editing is a paradigm shift in the field of cell therapy, immuno-oncology, and medicine in general and that’s where Cellectis is trying to make the point." − André Choulika Chairman & CEO, CEllectis
I don’t think anything could be more exciting than trying to have a major effect on cancer patients. It’s a privilege, to be honest, to be involved in such an exciting field." − James Noble CEO, Adaptimmune
Cancer is an individualized disease. Our technology lends itself towards treating a patient’s individualized antigens that are discreet and personal to that patient.”" − Dan O’Connor CEO, Advaxis